Published in Hypertension on January 02, 2007
Chemistry and antihypertensive effects of tempol and other nitroxides. Pharmacol Rev (2008) 1.91
The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl Recept Signal (2007) 1.89
Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther (2010) 1.66
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest (2011) 1.35
Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol (2010) 1.35
The physiological impact of the serum and glucocorticoid-inducible kinase SGK1. Curr Opin Nephrol Hypertens (2009) 1.35
Reactive oxygen species, NADPH oxidases, and hypertension. Hypertension (2010) 1.24
Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol (2013) 1.22
Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal (2013) 1.13
Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes (2010) 1.12
Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis (2011) 1.10
Aldosterone and glomerular podocyte injury. Clin Exp Nephrol (2008) 1.07
Targeting SGK1 in diabetes. Expert Opin Ther Targets (2009) 1.02
Natriuretic peptide receptor guanylyl cyclase-A protects podocytes from aldosterone-induced glomerular injury. J Am Soc Nephrol (2012) 1.01
Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease. Nat Rev Nephrol (2013) 1.01
Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPARγ. Am J Pathol (2011) 0.99
Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther (2009) 0.98
Increased production of superoxide anion contributes to dysfunction of the arteriovenous fistula. Am J Physiol Renal Physiol (2012) 0.94
The podocyte power-plant disaster and its contribution to glomerulopathy. Front Endocrinol (Lausanne) (2014) 0.93
Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch (2008) 0.92
Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. J Hypertens (2011) 0.92
Role of NADPH oxidase-mediated reactive oxygen species in podocyte injury. Biomed Res Int (2013) 0.92
TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am J Physiol Renal Physiol (2013) 0.92
Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol (2009) 0.89
Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options. Pediatr Nephrol (2013) 0.88
Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol (2010) 0.87
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept (2012) 0.87
Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. PLoS One (2012) 0.86
Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens (2011) 0.86
Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study. Vasc Health Risk Manag (2009) 0.85
Endothelin and the podocyte. Clin Kidney J (2012) 0.85
The roles of oxidative stress, endoplasmic reticulum stress, and autophagy in aldosterone/mineralocorticoid receptor-induced podocyte injury. Lab Invest (2015) 0.84
Oxidant Mechanisms in Renal Injury and Disease. Antioxid Redox Signal (2016) 0.84
Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. Nephrol Dial Transplant (2010) 0.83
Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Transl Res (2009) 0.83
Role of mineralocorticoid receptor/Rho/Rho-kinase pathway in obesity-related renal injury. Int J Obes (Lond) (2011) 0.83
Dexamethasone increases the phosphorylation of nephrin in cultured podocytes. Clin Exp Nephrol (2011) 0.81
Podocytes. F1000Res (2016) 0.81
The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Fail Rev (2012) 0.80
Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease. Clin Sci (Lond) (2015) 0.80
SGK, renal function and hypertension. J Nephrol (2010) 0.80
The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep (2011) 0.79
High-sodium intake aggravates myocardial injuries induced by aldosterone via oxidative stress in Sprague-Dawley rats. Acta Pharmacol Sin (2012) 0.79
Effect of aldosterone and its antagonist on the expression of PAI-1 and TGF-β1 in rat hepatic stellate cells. Int J Clin Exp Med (2014) 0.79
Serum- and glucocorticoid-inducible kinase 1 in the regulation of renal and extrarenal potassium transport. Clin Exp Nephrol (2011) 0.79
Differential effects of 17beta-estradiol and of synthetic progestins on aldosterone-salt-induced kidney disease. Toxicol Pathol (2009) 0.79
Aldosterone and TGF-β1 synergistically increase PAI-1 expression in hepatic stellate cells of rats. Int J Clin Exp Pathol (2015) 0.78
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart Vessels (2012) 0.78
Myeloid mineralocorticoid receptor activation contributes to progressive kidney disease. J Am Soc Nephrol (2014) 0.77
Nuclear hormone receptors in podocytes. Cell Biosci (2012) 0.77
Mineralocorticoid Receptor Blocker Protects against Podocyte-Dependent Glomerulosclerosis. Nephron Extra (2012) 0.77
Involvement of renin-angiotensin-aldosterone system in calcium oxalate crystal induced activation of NADPH oxidase and renal cell injury. World J Urol (2015) 0.77
The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens (2016) 0.77
Mineralocorticoid receptor activation as an etiological factor in kidney diseases. Clin Exp Nephrol (2013) 0.76
Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet. Nutrients (2014) 0.76
Effects of p53 on aldosterone-induced mesangial cell apoptosis in vivo and in vitro. Mol Med Rep (2016) 0.76
Spironolactone promotes autophagy via inhibiting PI3K/AKT/mTOR signalling pathway and reduce adhesive capacity damage in podocytes under mechanical stress. Biosci Rep (2016) 0.76
Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy. Cureus (2015) 0.76
Natriuretic Peptide Receptor Guanylyl Cyclase-A in Podocytes is Renoprotective but Dispensable for Physiologic Renal Function. J Am Soc Nephrol (2016) 0.76
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors. PLoS One (2014) 0.75
Podocyte Injury and Albuminuria in Experimental Hyperuricemic Model Rats. Oxid Med Cell Longev (2017) 0.75
Deletion of Rac1GTPase in the Myeloid Lineage Protects against Inflammation-Mediated Kidney Injury in Mice. PLoS One (2016) 0.75
Endoplasmic Reticulum Chaperon Tauroursodeoxycholic Acid Attenuates Aldosterone-Infused Renal Injury. Mediators Inflamm (2016) 0.75
Natriuretic peptide receptor guanylyl cyclase-A pathway counteracts glomerular injury evoked by aldosterone through p38 mitogen-activated protein kinase inhibition. Sci Rep (2017) 0.75
Increased microparticle production and impaired microvascular endothelial function in aldosterone-salt-treated rats: protective effects of polyphenols. PLoS One (2012) 0.75
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 3.03
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology (2002) 3.00
Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med (2011) 2.68
Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nat Med (2005) 2.59
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
Combination of two urinary biomarkers predicts acute kidney injury after adult cardiac surgery. Ann Thorac Surg (2012) 2.39
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med (2008) 2.25
Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med (2011) 2.18
Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol (2005) 2.05
Hemoglobin is expressed by mesangial cells and reduces oxidant stress. J Am Soc Nephrol (2008) 1.99
Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol (2007) 1.98
Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension (2007) 1.93
Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet (2002) 1.89
QTL mapping of domestication-related traits in soybean (Glycine max). Ann Bot (2007) 1.85
Real-time in vivo virtual histology of colorectal lesions when using the endocytoscopy system. Gastrointest Endosc (2006) 1.84
Association of eNOS Glu298Asp polymorphism with end-stage renal disease. Hypertension (2002) 1.83
Epidermal lamellar granules transport different cargoes as distinct aggregates. J Invest Dermatol (2004) 1.80
Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol (2003) 1.79
Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int (2005) 1.78
Endoplasmic reticulum stress induces autophagy in renal proximal tubular cells. Nephrol Dial Transplant (2009) 1.76
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res (2008) 1.75
Blockade of the nuclear factor-κB pathway in the endothelium prevents insulin resistance and prolongs life spans. Circulation (2012) 1.75
Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med (2010) 1.74
Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension (2002) 1.73
Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension (2006) 1.71
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens (2003) 1.70
Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int (2002) 1.68
Urinary sediment podocalyxin in children with glomerular diseases. Nephron Clin Pract (2003) 1.64
Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res (2009) 1.63
Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation. Cardiovasc Res (2012) 1.61
IRBIT, an inositol 1,4,5-trisphosphate receptor-binding protein, specifically binds to and activates pancreas-type Na+/HCO3- cotransporter 1 (pNBC1). Proc Natl Acad Sci U S A (2006) 1.61
Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol (2003) 1.60
siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol (2010) 1.58
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant (2008) 1.56
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension (2006) 1.55
Isolation and potential existence of side population cells in adult human kidney. Int J Urol (2008) 1.55
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol (2014) 1.55
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab (2004) 1.54
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol (2004) 1.52
Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int (2008) 1.52
Antioxidant, EUK-8, prevents murine dilated cardiomyopathy. Circ J (2009) 1.52
Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol (2006) 1.51
Paradoxical mineralocorticoid receptor activation and left ventricular diastolic dysfunction under high oxidative stress conditions. J Hypertens (2008) 1.49
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol (2006) 1.49
Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol (2005) 1.47
SRC-family kinase Fyn phosphorylates the cytoplasmic domain of nephrin and modulates its interaction with podocin. J Am Soc Nephrol (2004) 1.47
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone (2009) 1.47
Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. J Bone Miner Res (2002) 1.44
Endogenous prostaglandin D2 synthesis reduces an increase in plasminogen activator inhibitor-1 following interleukin stimulation in bovine endothelial cells. J Hypertens (2002) 1.43
Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol (2006) 1.41
Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension (2003) 1.40
Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest (2005) 1.38
Lung injury following acute kidney injury: kidney-lung crosstalk. Clin Exp Nephrol (2011) 1.38
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res (2003) 1.38
Wrong primer for rat angiotensinogen mRNA. Am J Physiol Renal Physiol (2005) 1.38
Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (2) Assessment of salt intake in the management of hypertension. Hypertens Res (2007) 1.37
Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J Am Soc Nephrol (2006) 1.37
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int (2002) 1.37
Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab (2005) 1.36
Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int (2004) 1.36
Blockade of CXCL10 protects mice from acute colitis and enhances crypt cell survival. Eur J Immunol (2002) 1.36
Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest (2011) 1.35
Protective role of hypoxia-inducible factor-2alpha against ischemic damage and oxidative stress in the kidney. J Am Soc Nephrol (2007) 1.35
Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension (2002) 1.34
Central control of bone remodeling by neuromedin U. Nat Med (2007) 1.32
Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab (2007) 1.31
Musculin/MyoR is expressed in kidney side population cells and can regulate their function. J Cell Biol (2005) 1.31
Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci (2004) 1.31
Functional analysis of NBC1 mutants associated with proximal renal tubular acidosis and ocular abnormalities. J Am Soc Nephrol (2005) 1.31
Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid (2010) 1.30
Localization of propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol (2012) 1.27
Hypoxia and hypoxia-inducible factor in renal disease. Nephron Exp Nephrol (2008) 1.26
Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int (2004) 1.25
Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int (2005) 1.24
Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol (2003) 1.24
Expression of NG,NG-dimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes (2007) 1.23
miR-200b precursor can ameliorate renal tubulointerstitial fibrosis. PLoS One (2010) 1.23
Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol (2009) 1.21
Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol (2006) 1.21
Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension. Hypertension (2007) 1.20
Mutational and functional analysis of SLC4A4 in a patient with proximal renal tubular acidosis. Pflugers Arch (2004) 1.19
Common variation in GPC5 is associated with acquired nephrotic syndrome. Nat Genet (2011) 1.17
Attenuation of folic acid-induced renal inflammatory injury in platelet-activating factor receptor-deficient mice. Am J Pathol (2006) 1.16